We are live on
!
Find out more
Denali Therapeutics
DNLI
DNLI
217 hedge funds and large institutions have $3.69B invested in Denali Therapeutics in 2024 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 79 increasing their positions, 59 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
72% more call options, than puts
Call options by funds: $2.01M | Put options by funds: $1.17M
71% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 21
34% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 59
28% more capital invested
Capital invested by funds: $2.88B → $3.69B (+$815M)
7% more funds holding
Funds holding: 203 → 217 (+14)
1.65% more ownership
Funds ownership: 86.88% → 88.53% (+1.7%)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Holders
217
Holders Change
+14
Holders Change %
+6.9%
% of All Funds
3.12%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
36
Increased
79
Reduced
59
Closed
21
Calls
$2.01M
Puts
$1.17M
Net Calls
+$840K
Net Calls Change
-$1.46M
Top Buyers
Top Sellers
| 1 |
TPC
Takeda Pharmaceutical Company
Tokyo,
Japan
|
-$97.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17.8M |
| 3 |
Millennium Management
New York
|
-$13.9M |
| 4 |
YCM
Yiheng Capital Management
San Francisco,
California
|
-$13.6M |
| 5 |
AG
Artal Group
Luxembourg
|
-$11.7M |
